| Literature DB >> 35795794 |
Yunliang Guo1,2,3,4,5, Shuo Zhao6, Xunyao Hou1,4,5, Shanjing Nie1,4,5, Song Xu1,4,5, Yan Hong1,4,5, Yali Chen7, Shougang Guo7,8, Xueping Liu1,4,5, Zhangyong Xia2,9.
Abstract
Background: Several reports have indicated potential cognitive decline for cerebral small vessel disease (CSVD), especially in attention domain, whereas the attentional function at network level is still elusive. In this study, we used the attention network test (ANT) paradigm to characterize the efficiency of the alerting, orienting, and executive control networks in patients with CSVD and explore possible correlations between attention network efficiencies and obtained CSVD total score.Entities:
Keywords: alerting; attention; attention network test; cerebral small vessel disease; executive control; orienting; total CSVD score
Year: 2022 PMID: 35795794 PMCID: PMC9251063 DOI: 10.3389/fneur.2022.865307
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Figure 1Schematic illustrations of original ANT paradigm. (A) Samples of four cue conditions, including no cue, center cue, double cue, and spatial cues. (B) Samples of three target types, including congruent, incongruent, and neutral stimuli. (C) Experimental procedures of trials in ANT. In this example, a double cue preceded an incongruent target, and the correct response was right button press.
Demographic, clinical, and imaging characteristics of patients with CSVD and healthy controls.
|
|
|
|
| |
|---|---|---|---|---|
| Number | 31 | 30 | ||
| Age, years (range) | 60.45 ± 7.47 | 58.67 ± 7.61 | 0.359 | |
| Gender, male/female | 17/14 | 15/15 | 0.705 | |
| Education, years | 11 (8–12) | 12 (9–12) | 0.359 | |
| BMI, kg/m2 (range) | 25.38 ± 2.59 | 24.65 ± 2.55 | 0.276 | |
| Hypertension (percentage) | 19 (61.29%) | – | ||
| Diabetes mellitus (percentage) | 10 (32.26%) | – | ||
| Hyperlipidemia (percentage) | 17 (54.84%) | – | ||
| Coronary heart disease (percentage) | 7 (22.58%) | – | ||
| Total CSVD score | 2 (1–2.5) | – |
Continuous variables were expressed as mean ± SD or median (interquartile range).
Categorical variables were expressed as n (%).
Student's t-test was used in analyses of age and BMI.
Mann–Whitney U test was used in analysis of education.
χ.
BMI, body mass index.
Neuropsychological and anxiety/depression/somatic symptom assessments of patients with CSVD and healthy controls.
|
|
|
|
| |
|---|---|---|---|---|
| MoCA | 28 (25–29) | 28 (27–29) | 1.70 | 0.090 |
| Visuospatial function | 4 (3–4) | 4 (3–4) | 0.83 | 0.405 |
| Executive function | 7 (7–8) | 8 (7–8) | 2.09 |
|
| Language | 5 (5–6) | 5 (5–6) | 0.00 | 1.000 |
| Attention and concentration | 3 (2–3) | 3 (3–3) | 1.70 | 0.089 |
| Calculation | 3 (3–3) | 3 (3–3) | 1.15 | 0.250 |
| Memory | 4 (3–5) | 5 (4–5) | 1.05 | 0.292 |
| Orientation | 6 (6–6) | 6 (6–6) | 0.43 | 0.671 |
| GAD-7 | 2 (1–5) | 2 (2–3) | −0.57 | 0.570 |
| PHQ-9 | 3 (1–4) | 2.5 (2–3) | −0.80 | 0.422 |
| PHQ-15 | 3 (1.5–4.5) | 2 (2–3) | −1.25 | 0.213 |
Data were expressed as median (interquartile range).
Visuospatial function, executive function, language, attention and concentration, calculation, memory as well as orientation are subdomains of MoCA.
Visuospatial function refers to copy cube and draw clock tests.
Executive function refers to alternating trail making, abstraction, verbal fluency, copy cube and draw clock tests.
Language refers to naming, sentence repetition and verbal fluency tests.
Attention and concentration refer to vigilance and digit span tests.
Calculation refers to serial 7s test.
Memory refers to delayed recall and verbal fluency tests.
Orientation refers to temporal and spatial orientation tests.
P < 0.05 by Mann-Whitney U test (two-tailed) (indicated as bold).
MoCA: Montreal Cognitive Assessment; GAD-7. The Generalized Anxiety Disorder-7; PHQ-9, The Patient Health Questionnaire-9; PHQ-15, The Patient Health Questionnaire-15.
Mean reaction time (ms) under each condition for patients with CSVD and healthy controls.
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Patients with CSVD | Congruent | 772.47 ± 113.02 | 753.71 ± 134.38 | 739.39 ± 116.35 | 726.91 ± 125.14 |
| Incongruent | 876.56 ± 112.13 | 860.60 ± 120.55 | 855.05 ± 118.31 | 837.49 ± 123.20 | |
| Neutral | 758.99 ± 115.49 | 742.64 ± 128.62 | 713.46 ± 111.22 | 721.45 ± 121.15 | |
| Healthy controls | Congruent | 621.90 ± 73.28 | 614.24 ± 77.22 | 589.50 ± 74.06 | 579.50 ± 71.97 |
| Incongruent | 695.60 ± 74.55 | 697.68 ± 76.45 | 664.91 ± 74.48 | 643.09 ± 74.28 | |
| Neutral | 618.55 ± 70.96 | 598.09 ± 71.46 | 575.49 ± 68.08 | 559.00 ± 71.30 | |
Data were expressed as mean ± SD.
Attention network efficiencies of patients with CSVD and healthy controls.
|
|
|
|
|
|
|---|---|---|---|---|
| Alerting (ms) (range) | 33.38 ± 12.40 | 35.38 ± 13.06 | 0.540 | |
| Orienting (ms) (range) | 23.70 ± 10.58 | 42.81 ± 12.92 |
| |
| Executive control (ms) (range) | 109.31 ± 26.01 | 74.03 ± 14.27 |
| |
| Overall RT (ms) (range) | 778.47 ± 115.17 | 620.29 ± 69.44 |
| |
| Overall accuracy (%) | 97.92 | 98.44 |
|
Data were expressed as mean ± SD or median (interquartile range).
P < 0.05 by Mann–Whitney U test;
P < 0.001 by Student's t-test (all indicated as bold).
ANT, attention network test; RT, reaction time.
Correlations between attention network efficiencies/MoCA and total CSVD score/anxiety, depression, somatic symptom scores in patients with CSVD.
|
|
|
|
| |
|---|---|---|---|---|
|
|
|
|
|
|
| Alerting network efficiency |
| −0.07 (0.725) | −0.09 (0.635) | −0.22 (0.231) |
| Orienting network efficiency |
| −0.03 (0.874) | 0.08 (0.688) | −0.32 (0.082) |
| Executive control network efficiency |
| 0.31 (0.089) | 0.03 (0.859) | 0.17 (0.353) |
| Overall RT | 0.18 (0.340) | −0.08 (0.666) | 0.07 (0.718) | 0.08 (0.675) |
| Overall accuracy | 0.01 (0.949) | 0.04 (0.829) | −0.25 (0.167) | −0.12 (0.521) |
| MoCA | −0.24 (0.186) | −0.19 (0.296) | −0.30 (0.101) | −0.35 (0.053) |
| Executive function | −0.09 (0.617) | −0.31 (0.092) | −0.19 (0.309) | −0.26 (0.166) |
P < 0.05,
P < 0.01 by Spearman's correlations (two-tailed) indicated as bold.
GAD-7, The Generalized Anxiety Disorder-7; PHQ-9, The Patient Health Questionnaire-9; PHQ-15, The Patient Health Questionnaire-15; MoCA, Montreal Cognitive Assessment.